RS60883B1 - Metodi lečenja tauopatije - Google Patents
Metodi lečenja tauopatijeInfo
- Publication number
- RS60883B1 RS60883B1 RS20200796A RSP20200796A RS60883B1 RS 60883 B1 RS60883 B1 RS 60883B1 RS 20200796 A RS20200796 A RS 20200796A RS P20200796 A RSP20200796 A RS P20200796A RS 60883 B1 RS60883 B1 RS 60883B1
- Authority
- RS
- Serbia
- Prior art keywords
- tauopathy
- treating
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361833355P | 2013-06-10 | 2013-06-10 | |
| PCT/US2013/055203 WO2014028777A2 (en) | 2012-08-16 | 2013-08-15 | Methods of treating a tauopathy |
| US14/092,539 US8926974B2 (en) | 2012-08-16 | 2013-11-27 | Methods of treating a tauopathy |
| EP14734364.4A EP3007726B1 (en) | 2013-06-10 | 2014-06-09 | Methods of treating a tauopathy |
| PCT/US2014/041553 WO2014200921A1 (en) | 2013-06-10 | 2014-06-09 | Methods of treating a tauopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60883B1 true RS60883B1 (sr) | 2020-11-30 |
Family
ID=52022687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20200796A RS60883B1 (sr) | 2013-06-10 | 2014-06-09 | Metodi lečenja tauopatije |
Country Status (18)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014028777A2 (en) * | 2012-08-16 | 2014-02-20 | Ipierian, Inc. | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽，抗Tau抗体，及其使用方法 |
| AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| TWI827405B (zh) | 2015-06-05 | 2023-12-21 | 美商建南德克公司 | 抗-ｔａｕ抗體及使用方法 |
| JP6949102B2 (ja) | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
| FR3058143B1 (fr) * | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| JP7193457B2 (ja) | 2016-12-07 | 2022-12-20 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
| KR20200018502A (ko) * | 2017-06-16 | 2020-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 타우병증 치료를 위한 조성물 및 방법 |
| JOP20200074A1 (ar) | 2017-10-16 | 2020-04-30 | Eisai R&D Man Co Ltd | أجسام مضادة ضد tau واستخداماتها |
| JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
| JP2022043373A (ja) * | 2018-12-28 | 2022-03-16 | 国立大学法人京都大学 | 大脳皮質細胞からのｌ１ｃａｍ陽性細胞の取得およびその細胞製剤としての使用 |
| CN113631573B (zh) * | 2019-03-25 | 2024-06-04 | 国家医疗保健研究所 | 抗Tau抗体及其在制备用于治疗疾病的药物中的用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US6010913A (en) | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
| BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| SG119177A1 (en) | 1994-12-09 | 2006-02-28 | Imp College Innovations Ltd | Identification of genes |
| AU4188196A (en) | 1994-12-22 | 1996-07-10 | Nissan Chemical Industries Ltd. | Organobismuth derivatives and process for producing the same |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| DK0939647T4 (da) | 1996-08-27 | 2006-10-23 | Novartis Vaccines & Diagnostic | Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US6046305A (en) | 1997-12-12 | 2000-04-04 | Macromed, Inc. | Heterofunctionalized star-shaped poly(ethylene gycols) for protein modification |
| US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
| EP1250600B1 (en) | 2000-01-24 | 2006-10-11 | Innogenetics N.V. | Diagnosis of tauopathies determining tau/phospho-tau ratio |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| AU2002337498B2 (en) | 2001-09-21 | 2006-08-10 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
| KR20070034512A (ko) | 2004-06-18 | 2007-03-28 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| CA2745499A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
| US9605054B2 (en) * | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| NZ609984A (en) * | 2010-10-11 | 2015-05-29 | Biogen Idec Internat Neuroscience Gmbh | Human anti-tau antibodies |
| EP2670434B1 (en) * | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| WO2014028777A2 (en) * | 2012-08-16 | 2014-02-20 | Ipierian, Inc. | Methods of treating a tauopathy |
| US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
-
2014
- 2014-06-09 BR BR112015030356A patent/BR112015030356A2/pt active Search and Examination
- 2014-06-09 LT LTEP14734364.4T patent/LT3007726T/lt unknown
- 2014-06-09 DK DK14734364.4T patent/DK3007726T3/da active
- 2014-06-09 CA CA2914768A patent/CA2914768A1/en not_active Abandoned
- 2014-06-09 EP EP20162335.2A patent/EP3760228A1/en not_active Withdrawn
- 2014-06-09 EA EA201592203A patent/EA039554B1/ru unknown
- 2014-06-09 MX MX2015016240A patent/MX370723B/es active IP Right Grant
- 2014-06-09 EP EP14734364.4A patent/EP3007726B1/en active Active
- 2014-06-09 HU HUE14734364A patent/HUE050485T2/hu unknown
- 2014-06-09 SI SI201431606T patent/SI3007726T1/sl unknown
- 2014-06-09 JP JP2016519574A patent/JP6446443B2/ja not_active Expired - Fee Related
- 2014-06-09 ES ES14734364T patent/ES2800827T3/es active Active
- 2014-06-09 WO PCT/US2014/041553 patent/WO2014200921A1/en active Application Filing
- 2014-06-09 CN CN201480032717.2A patent/CN105339002B/zh not_active Expired - Fee Related
- 2014-06-09 CA CA3173775A patent/CA3173775A1/en active Pending
- 2014-06-09 PT PT147343644T patent/PT3007726T/pt unknown
- 2014-06-09 PL PL14734364T patent/PL3007726T3/pl unknown
- 2014-06-09 RS RS20200796A patent/RS60883B1/sr unknown
-
2015
- 2015-11-25 MX MX2019015604A patent/MX2019015604A/es unknown
-
2020
- 2020-07-03 CY CY20201100614T patent/CY1123672T1/el unknown
- 2020-07-07 HR HRP20201064TT patent/HRP20201064T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3007726T (pt) | 2020-06-22 |
| SI3007726T1 (sl) | 2020-11-30 |
| JP2016525502A (ja) | 2016-08-25 |
| CN105339002B (zh) | 2019-06-28 |
| CN105339002A (zh) | 2016-02-17 |
| BR112015030356A2 (pt) | 2017-12-05 |
| MX2019015604A (es) | 2020-02-26 |
| EP3760228A1 (en) | 2021-01-06 |
| CY1123672T1 (el) | 2022-03-24 |
| JP6446443B2 (ja) | 2018-12-26 |
| CA2914768A1 (en) | 2014-12-18 |
| WO2014200921A1 (en) | 2014-12-18 |
| CA3173775A1 (en) | 2014-12-18 |
| DK3007726T3 (da) | 2020-07-06 |
| HRP20201064T1 (hr) | 2021-01-22 |
| EP3007726B1 (en) | 2020-04-08 |
| MX370723B (es) | 2019-12-20 |
| EP3007726A1 (en) | 2016-04-20 |
| LT3007726T (lt) | 2020-09-10 |
| EA039554B1 (ru) | 2022-02-09 |
| PL3007726T3 (pl) | 2021-01-11 |
| EA201592203A1 (ru) | 2016-05-31 |
| MX2015016240A (es) | 2016-08-11 |
| ES2800827T3 (es) | 2021-01-04 |
| HUE050485T2 (hu) | 2020-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237153A0 (en) | Methods of therapeutic treatment | |
| PL3007726T3 (pl) | Metody leczenia tauopatii | |
| GB201312991D0 (en) | Process | |
| EP2945639A4 (en) | METHOD FOR THE TREATMENT OF HEART DISEASES | |
| SG11201508447TA (en) | Expression process | |
| HK1215164A1 (zh) | 處理方法 | |
| GB201304872D0 (en) | Treatment | |
| IL241096A0 (en) | Treatment methods | |
| GB201302441D0 (en) | Process | |
| GB201415000D0 (en) | Improved process | |
| GB201322992D0 (en) | New Process | |
| GB201316901D0 (en) | Method of treating a borehole | |
| GB201317756D0 (en) | New process | |
| GB201313211D0 (en) | New process | |
| GB201307310D0 (en) | Treatment | |
| PL3041506T3 (pl) | Sposób leczenia | |
| GB201322778D0 (en) | Method of treatment | |
| GB201314882D0 (en) | Method of treatment | |
| GB201321442D0 (en) | Expression process | |
| GB201320339D0 (en) | Expression Process | |
| GB201319930D0 (en) | Expression process | |
| GB201321115D0 (en) | Treatment | |
| GB201311837D0 (en) | Expression Process | |
| GB201308017D0 (en) | Expression process | |
| GB201309238D0 (en) | Treatment |